Scienture Holdings, Inc. announced a 449% increase in Q1 2026 revenue to $56K and a gross margin expansion to 95.6%, driven by growing sales of its FDA-approved hypertension drug Arbli™. The company also secured a third patent for Arbli™, extending market exclusivity through 2041, and received an Orange Book patent for REZENOPY™, a high-dose naloxone nasal spray for opioid overdose treatment. Scienture formalized commercial agreements expanding REZENOPY™'s market access and raised $11 million in non-dilutive debt to support growth and R&D. The firm expects continued growth from Arbli™ and plans to launch REZENOPY™ in the second half of 2026, aiming for profitability in 2027.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
